Blue Trust’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$333K Buy
2,113
+15
+0.7% +$2.37K ﹤0.01% 610
2026
Q2
$332K Buy
2,098
+2,086
+17,383% +$282K ﹤0.01% 623
2026
Q1
$1.53K Sell
12
-50
-81% -$6.24K ﹤0.01% 2186
2025
Q4
$7.56K Sell
62
-73
-54% -$8.37K ﹤0.01% 1928
2025
Q3
$13.5K Buy
+135
New +$12.2K ﹤0.01% 1782
2024
Q4
– Sell
-10
Closed -$927 – 3018
2024
Q3
$927 Buy
+10
New +$983 ﹤0.01% 2707
2022
Q3
– Sell
-16,009
Closed -$1.44M – 2355
2022
Q2
$1.44M Buy
+16,009
New +$1.2M 0.02% 117

Other funds holding XBI

Blue Trust's XBI Position: Q3 2026 in Review

Blue Trust increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.71% in Q3 2026, buying an estimated $2.37K and bringing the position to 2,113 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #610.

Blue Trust first reported a position in XBI in Q2 2022 and has held it in 7 quarters since. The position peaked at $1.44M in Q2 2022. 820 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Blue Trust held 2,113 shares of State Street SPDR S&P Biotech ETF worth $333K as of Q3 2026.
  • Blue Trust bought 15 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $2.37K.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #610 holding.
  • Blue Trust first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and has held it in 7 quarters since.
  • Blue Trust's State Street SPDR S&P Biotech ETF position peaked at $1.44M in Q2 2022.
  • 820 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.